Cybin CEO to Speak at Psychedelic Science 2025 Conference

Cybin ( (TSE:CYBN) ) has issued an announcement.

Cybin announced that its CEO, Doug Drysdale, will participate in a panel discussion at the Psychedelic Science 2025 Conference in Denver. This participation highlights Cybin’s commitment to advancing clinical work in psychedelic therapeutics, aiming to address unmet medical needs in mental health treatment. The conference serves as a platform for sharing insights and engaging with global experts, emphasizing the growing recognition of psychedelic therapeutics in medical circles.

The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$114.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.

Spark’s Take on TSE:CYBN Stock

According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.

Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.

To see Spark’s full report on TSE:CYBN stock, click here.

More about Cybin

Cybin is a clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is working on treatments for mental health disorders, including major depressive disorder and generalized anxiety disorder, through compounds like CYB003 and CYB004. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Technical Sentiment Signal: Hold

Current Market Cap: C$1.97M

For an in-depth examination of CYBN stock, go to TipRanks’ Stock Analysis page.